SOURCE Research and Markets
R&D activities in the Diabetic Neuropathy sector are growing in terms of an increase in the number of mergers and acquisitions. Big pharmaceutical companies take up later-stage products from small companies, where efficacy has already been demonstrated, thereby cutting down initial R&D expenditure.
For instance, in March 2013, BioDelivery Sciences International Inc. in-licensed a patented topical formulation of clonidine gel from Arcion Therapeutics Inc. for the treatment of indications including diabetic neuropathy. In July 2013, Acorda Therapeutics acquired two candidates for neuropathic pain including NP-1998, a topical capsaicin solution, from NeurogesX Inc. In-licensing by big pharmaceutical companies, in turn, diverts funds to be spent by the smaller companies on marketing and commercialization to R&D development.
According to the report, the Global Diabetic Neuropathy market is driven by several factors, of which the increase in the global diabetic population is one of the major drivers. The incidence and prevalence rate of diabetes is growing continuously, mainly because of the adoption of a sedentary form of life and unhealthy eating habits accompanied by increased life expectancy.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Geographical Segmentation
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
16. Key Vendor Analysis
17. Pipeline Analysis
18. Other Reports in this Series
For more information visit http://www.researchandmarkets.com/research/q8x6s6/global_diabetic
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.